Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the efficacy and toxicities of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer (NSCLC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother. Pharmacol.

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Nature America, Inc

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): Feb 2011

Volume: 67

Issue: 2

Affiliations

[1 ] Oncology Department, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People's Hospital, No. 183 Yiling Road, Yichang, Hubei 443002, China. xuxinhua@medmail.com.cn

Article

DOI: 10.1007/s00280-010-1450-6

PubMed ID: 20844881

SO-VID: 5ab21a2d-aa92-47f3-8e5c-3b83d38d6e64

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by